HBV and Liver Cancer
NOTE: This section contains only hepatitis B-related liver cancer (HCC) clinical trials, for a complete list, please click here.
*CHB=Chronic hepatitis B, Liver cancer=hepatocellular carcinoma or HCC
Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area –U.S.
Patients between the age of 18 & 90 who have been diagnosed with HCC or have a high risk of developing HCC due to HBV, HCV, fatty liver disease, etc. Contact: Dr. Dean L. Mann at 410-328-5512, firstname.lastname@example.org or Dr. Xin Wang at 301-496-2099 or email@example.com and refer to identifier – NCT00913757 (Study ID # 999909149, 09-C-N149)
Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma –U.S.
This is a phase II trial of Pembrolizumab (Keytruda) in patients with advanced, unresectable hepatocellular carcinoma. Contact Dr. Lynn Feun at 305-243-6606 or firstname.lastname@example.org and refer to identifier NCT02658019.
A Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Patients With Advanced Liver Cancer (CheckMate040) – U.S. and International
The first part of the study is the Dose Escalation Phase designed to establish the safety of nivolumab at different dose levels for each of the three cohorts (uninfected hepatocellular carcinoma (HCC) subjects, hepatitis C virus (HCV)-infected HCC subjects, and hepatitis B virus (HBV)-infected subjects). The second part of the study is the Expansion Phase designed to generate additional clinical data at specified doses for each of the 3 cohorts. For study contact information in each state, region or country, please go to the study’s description page and find the study location nearest you. The study’s sponsor is Bristol-Myers Squibb. Refer to the study identifier -- NCT01658878.
A Study of Nivolumab Compared to Sorafenib as a Primary Treatment in Patients With Advanced Hepatocellular Carcinoma -- US and International
The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma. For study contact information in each state, region or country, please go to the study’s description page and find the study location nearest you. The study’s sponsor is Bristol-Myers Squibb. Refer to the study identifier -- NCT02576509.
Adjuvant Entecavir for Postoperative HBV-HCC -- China
This study aims to compare the effect of antiviral therapy with entecavir and lamivudine for hepatitis B virus-related liver cancer (hepatocellular carcinoma) after radical hepatectomy. Included patients will randomly divide into two groups. Contact Jian-Hong Zhong at email@example.com or 86-771-5330855 and refer to identifier NCT02650271 (Study ID AEVT-HCC).
Follow-up Strategy of Chronic Hepatitis B for Early Detection and Diagnosis of Hepatocellular Carcinoma: A Randomized Control Trial – China
The aim of this study is to establish an all-round and convenient follow-up strategy of CHB for early detection and diagnosis of Hepatocellular Carcinoma (HCC), by investigating whether different surveillance time intervals and surveillance methods are beneficial for chronic hepatitis B and cirrhotic patients with different risk of HCC. Contact: Zhongzhen Su at Sun Yat-Sen University at 0086-020-85252010 or firstname.lastname@example.org and refer to identifier NCT02817685.
Study of Liver Resection With Versus Without Hepatic Inflow Occlusion for the HBV-related HCC (OHx-NOHx) – China}
The study aims to compare the perioperative and long-term outcomes of liver resection for HBV-related HCC with versus without hepatic inflow occlusion. Contact Dr. Shichun Lu at +86 10 68160801 or email@example.com and refer to identifier NCT02563158.
TCR-Redirected T Cell Infusions to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation - China
This study plans to recruit 10 subjects with Hepatitis B virus (HBV) related HCC after liver transplantation. The objective of the study is to assess the safety, tolerability and effectiveness of the HBV specific T cell receptor (HBV/TCR) redirected T cell in the target population. Contact Dr. Lietao Li at (65) 6224 6157 or firstname.lastname@example.org and refer to NCT02686372.
TCR-Redirected T Cell Infusions to Treat Recurrent Hepatocellular Carcinoma Post Liver Transplantation - China
This study plans to recruit 10 patients with Hepatitis B virus (HBV) related HCC who underwent liver transplantation and are confirmed to have recurrent HCC. The objective of the study is to assess the safety, tolerability and effectiveness of the HBV specific T cell receptor (HBV/TCR) redirected T cell in the target population. Contact Dr. Lietao Li at (65) 6224 6157 or email@example.com and refer to NCT02719782.
The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis – Egypt
Vitamin D levels may influence cancer development. Vitamin D receptor (VDR gene polymorphisms) have also been investigated as impacting chronic hepatitis B, primary biliary cirrhosis and autoimmune hepatitis. A significant association of VDR (ApaI) polymorphism with the development of HCC (liver cancer) in chronic HCV infection may help to identify those who are at high risk of developing HCC. Contact: Sherief Abd-elsalam at 00201095159522 or email firstname.lastname@example.org and refer to identifier NCT02461979.
Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the Response of Antiangiogenics Treatments in Hepatocellular Carcinoma (ETAFIRM) - France
This study liver examines the effectiveness of Perfusion MRI in its capacities to predict the response of HCC to antiangiogenic treatments. Contact Dr. Agnes Rode at =33 4 72 07 18 83 or email@example.com and refer to identifier NCT02585687.
Sonazoid Enhanced Liver Cancer Trial For Early Detection– Japan
Use of contrast enhanced ultrasound (US) using Sonazoid vs. conventional B-mode US for early HCC detection. Contact: Masatoshi Kudo at +81 72-366-0221 ext. 3149 or firstname.lastname@example.org, or Dr. KazuomiUeshima at +81-72-366-0221 ext. 3525, email@example.com and refer to identifier – NCT00822991 (Study ID# JLOG08001, UMIN000001612)
Boramae Hospital Liver Cirrhosis Patient Cohort Study- Korea
The goal of this study is to describe the natural history of a large number of patients with liver cirrhosis prospectively followed, and to identify predictors of the occurrence of hepatocellular carcinoma. Contact Sae Kyung Joo at 821089619285 or firstname.lastname@example.org and refer to identifier NCT01943318.
Hypofractionated Proton Beam Radiotherapy for Hepatocellular Carcinoma – Korea
This phase II study is to evaluate the effectiveness of hypofractionated proton beam therapy (PBT) for HCC patients in hepatitis B endemic area. Contact Tae Hyun Kim at 82-31-920-1725 or email@example.com and refer to identifier NCT01643824.
Hypofractionated Proton Beam Radiotherapy for Inoperable Hepatocellular Carcinoma – Korea
This phase II study is to evaluate the effectiveness of hypofractionated proton beam therapy (PBT) for Hepatocellular Carcinoma patients in hepatitis B endemic area. Contact Tae Hyun Kim at 82-31-920-1725 or firstname.lastname@example.org and refer to identifier NCT02395523.
Stereotactic Body Radiotherapy (SBRT) for UnresectableHepatocellular Carcinoma (SBRT for HCC) – Korea
This study evaluates the effectiveness and adverse event of SBRT in the patients who had solitary 3 cm or less size HCC without extrahepatic lesion and vascular involvement. Contact HeeChul Park at 82-2-3410-2612 or email@example.com and refer to identifier NCT01910909.
Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma – Saudi Arabia
This randomized controlled trial is designed to prospectively compare TACE and 90Y for treatment of patients with unresectable (BCLC intermediate stage) HCC. Contact Mohamed I Al Sebayel at firstname.lastname@example.org and refer to identifier NCT02729506.
The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC – Taiwan
This is a phase I clinical trial evaluating the safety and MTD of axitinib in combination with RT for advanced HCC. Contact Dr. Yu-Min Li at +886-28332211 ext 2031 or M001063@ms.skh.org.tw and refer to identifier NCT02814461.
HBV-host cfDNA as Minimal Residual Tumor Marker for HBV-related HCC (Liver Cancer) – Taiwan
HBV DNA integration has been found in the chromosomes of about 90% of HBV-related HCC and the integration site is unique to individual HCC. The HBV-host junction DNA fragment from one HCC is therefore a tumor-specific biomarker. Investigators will develop either HBV-specific inverse PCRs or capture-sequencing protocols to identify HBV integrations sites in the tumor chromosomes in patients who have had an HBV-related liver cancer tumor removed surgically. Contact: Pei-Jer Chen, PhD, MD, +886-2-23123456 ext 67072 or email email@example.com and refer to identifier NCT03020342.